ADEPT System Cancer Imager wins Illinois Tech’s $1 million Nayar Prize Competition

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Illinois Institute of Technology announced a cancer imaging research team is the winner of the final round of the university’s Nayar Prize, which includes a $500,000 personal award to team members. Including previous rounds, this brings the total amount won by this and other teams in the first Nayar Prize competition to $1 million.

The team of Kenneth Tichauer, Illinois Tech associate professor of biomedical engineering; and Jovan Brankov, Illinois Tech associate professor of electrical and computer engineering and of biomedical engineering, and director of the Advanced X-ray Imaging Laboratory developed the Agent-Dependent Early Photon Tomography Cancer Imager with the goal of finding tumors in lymph nodes of breast cancer patients at earlier stages.

The ADEPT System Cancer Imager dyes the entire lymph node, as opposed to a small sample. The combination of the special dyeing process and camera improvements provides a sharper picture of the tissue sample at the molecular level.

The result is a system that allows pathologists to find smaller tumors and prescribe a precise and personalized drug treatment for the patient. Team members estimate 40,000 more women will be properly diagnosed annually using the ADEPT imager.

The team is planning a clinical trial of the ADEPT system, in a partnership with Sanford Research in Sioux Falls, South Dakota, and the University of Chicago Department of Pathology.

The ADEPT Cancer Imager team was selected as one of three finalists for the inaugural Nayar Prize when the competition was announced in 2015, earning $100,000 to continue its research. It was selected from that pool as the sole phase II finalist, earning an additional $200,000 for further research. The team members can use the final, personal $500,000 award at their discretion with no restrictions.

Team members include Miles Wernick, Motorola Endowed Chair Professor of Electrical and Computer Engineering, director of the Medical Imaging Research Center and professor of biomedical engineering; Lori Andrews, distinguished professor of law and director of the Institute for Science, Law, and Technology at Chicago-Kent College of Law; and Yongyi Yang, Harris Perlstein Professor of Electrical and Computer Engineering and professor of biomedical engineering.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login